In this episode of Drop the Weight, we welcome Dr. Robert Todd Hurst back onto the show—for call it Round 2— to discuss everything that has happened in the world of GLP-1 weight loss medications in the 18 months since we last spoke with him. Unless you have been living under a very large rock somewhere, no doubt you have heard the news from all media and social media sources about the explosive rise of so-called "miracle" semaglutide drugs like Ozempic, Mounjaro and Tirzepatide both in the U.S. and worldwide. And beyond the celebrities touting it, you most likely have at least one friend or acquaintance who has dropped 30+ pounds in the last six months (and almost looks like a different person) who very likely is a GLP-1 patient. Basically, this stuff is everywhere, and we can't stop talking about it! This podcast covers just about everything you would want to know or ask about these medications, like: do they live up to the hype? What is the risk of regaining the weight you may lose while taking them? Are the dosages recommended by their pharmaceutical manufacturers too high? How big of a concern is muscle loss? We even talk about the issue of so-called "Ozempic face" and what Hurst separately identifies as his single greatest fear about these drugs. All of these questions taken into consideration, Hurst powerfully observes how GLP-1 medications are undoubtedly among the most fascinating and impactful molecules in healthcare today with effective treatment applications that reach beyond diabetes and obesity to heart disease, kidney disease and possibly even Parkinson's. Check it out! CLICK HERE TO GET == FREE MASTERCLASS - "Freedom From Food Noise": https://go.elizabethmcgann.com/start *** SHOW NOTES [ 00:40 ] Intro [ 03:20 ] No longer just a weight loss medication; applications to diabetes, obesity, heart and kidney diseases and possibly Parkinson's [ 06:15 ] Minimum effective dose [ 07:00 ] Many GLP-1 patients who go off the medication end up regaining most of the weight [ 09:20 ] Not a weight loss doctor; a better health and longer life practice with weight loss as a consequence [ 11:20 ] Importance of getting patients OFF these medications [ 13:40 ] "Muscle is youth" – The real issue of muscle loss and how Hurst deals with it with his GLP-1 patients [ 15:00 ] Metabolically optimized diets [ 18:20 ] Conflicts of interest in healthcare: doctors, patients, insurance and pharmaceutical companies [ 21:20 ] Pharmaceutical compounding of GLP-1s? [ 23:00 ] Microdosing [ 24:15 ] Most of Hurst's GLP1 patients take ⅕ of the pharmaceutically recommended dose [ 29:40 ] Is there a minimum obesity threshold? [ 35:20 ] 93 percent of Americans are insulin resistant [ 38:00 ] Ozempic face [ 40:15 ] Appropriate for teenagers? [ 42:00 ] Hurst's greatest fear about GLP1-s [ 48:20 ] Yerba Mate and Berberine [ 54:00 ] "Most of the diseases killing us are preventable" [ 56:15 ] HealthspanMD's patients who "don't want to leave healthy years on the table" *** Get Connected with Elizabeth McGann: CLICK HERE TO GET FREE MASTERCLASS: "Freedom From Food Noise": https://go.elizabethmcgann.com/start Coaching Website: http://www.ElizabethMcGann.com Instagram: http://www.instagram.com/elizabethmcgann Facebook: https://www.facebook.com/ElizabethMcGannWellness LinkedIn: https://www.linkedin.com/in/elizabethmcgann X/Twitter: https://twitter.com/ElizabethMcGann *** Learn more about Dr. Robert Todd Hurst: Instagram: https://www.instagram.com/healthspanmd/ Website: https://www.healthspanmd.com/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related